| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/19/2002 | US20020132842 Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them |
| 09/19/2002 | US20020132833 Caspase inhibitors and uses thereof |
| 09/19/2002 | US20020132827 Using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, "off-period." |
| 09/19/2002 | US20020132824 1,5-methylene-3-benzazepines used in treatment of neurological and psychological disorders,especially withdrawl from nicotine addiction |
| 09/19/2002 | US20020132822 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 09/19/2002 | US20020132818 Thienopyrimidines |
| 09/19/2002 | US20020132816 Estrogen agonists/antagonists for preventing breast cancer |
| 09/19/2002 | US20020132811 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
| 09/19/2002 | US20020132810 Novel heterocyclic amide derivatives |
| 09/19/2002 | US20020132809 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production |
| 09/19/2002 | US20020132807 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| 09/19/2002 | US20020132806 Treatment of atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X |
| 09/19/2002 | US20020132802 Cytoprotective polycyclic compounds |
| 09/19/2002 | US20020132796 Treatment or prevention of the diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid. |
| 09/19/2002 | US20020132775 Human potassium channel 1 and 2 proteins |
| 09/19/2002 | US20020132754 Producing pharmaceuticals for improving perception, concentration, learning and/or memory. |
| 09/19/2002 | US20020132324 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/19/2002 | US20020132296 Human Ste20-like stress activated serine/threonine kinase |
| 09/19/2002 | US20020132018 Use of non-alkalized cocoa solids in a drink |
| 09/19/2002 | US20020132001 Delayed-release formulation of aldosterone antagonist drug which when orally administered 6-12 hours prior to acrophase provides profile of plasma drug concentration corresponding to diurnal cycle of plasma aldosterone concentration |
| 09/19/2002 | DE10112768A1 New heterocyclic-substituted phenyl compounds, are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, restenosis or tumor diseases |
| 09/19/2002 | DE10112151A1 New 5-(4-(indolyl-alkyl)-piperazino)-benzofuran-2-carboxamides useful e.g. for treating depression, anxiety, psychiatric or cerebral disorders or pain, are 5-HT-1A receptor agonists and 5-HT reuptake inhibitors |
| 09/19/2002 | DE10111842A1 Antithrombotische Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel Antithrombotic carboxamides, their preparation and their use as medicaments |
| 09/19/2002 | DE10110754A1 Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use |
| 09/19/2002 | DE10110438A1 Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and their use |
| 09/19/2002 | DE10058461A1 Substituierte Cyclohexanderivate und ihre Verwendung Substituted cyclohexane derivatives and their use |
| 09/19/2002 | CA2702192A1 Igf antagonist peptides |
| 09/19/2002 | CA2473979A1 Method for identifying inhibitors of g protein coupled receptor signaling |
| 09/19/2002 | CA2473156A1 Rxr activating molecules |
| 09/19/2002 | CA2470152A1 Transfection complexes comprising a novel peptide as cell surface receptor binding component |
| 09/19/2002 | CA2440974A1 High affinity integrin polypeptides and uses thereof |
| 09/19/2002 | CA2440834A1 Anti-epileptogenic agents |
| 09/19/2002 | CA2440670A1 Agent for therapeutic and/or prophylactic treatment of diabetic ischemic heart disease |
| 09/19/2002 | CA2440647A1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same |
| 09/19/2002 | CA2440641A1 Chronotherapeutic dosage forms containing glucocorticosteroid |
| 09/19/2002 | CA2440618A1 Immunoglobulin superfamily proteins |
| 09/19/2002 | CA2440282A1 Diphenyl derivatives |
| 09/19/2002 | CA2440167A1 Method to prepare microparticles that contain metoprolol |
| 09/19/2002 | CA2440166A1 Salvia hispanica l. (chia) in the management and treatment of cardiovascular disease, diabetes and associated risk factors |
| 09/19/2002 | CA2439920A1 Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
| 09/19/2002 | CA2439735A1 Igf antagonist peptides |
| 09/19/2002 | CA2439612A1 Modulation of smooth muscle cell proliferation |
| 09/19/2002 | CA2439498A1 Somatostatin antagonists |
| 09/19/2002 | CA2439301A1 Compositions comprising matrine and dictamnine for treating or preventing cancer and other diseases |
| 09/19/2002 | CA2439231A1 Antithrombotic carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions |
| 09/19/2002 | CA2438874A1 Fluorinated trienes and their use as rxr modulators |
| 09/19/2002 | CA2438586A1 Retinoid x receptor modulators |
| 09/19/2002 | CA2438401A1 Pharmaceutical composition |
| 09/19/2002 | CA2438164A1 Use of preparations containing selenite or selenate |
| 09/19/2002 | CA2437958A1 Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors |
| 09/19/2002 | CA2437932A1 Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
| 09/19/2002 | CA2433353A1 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 09/18/2002 | WO2001070678A2 Substituted biphenyl derivatives |
| 09/18/2002 | EP1241257A1 Novel tachykinin-like polypeptides and use thereof |
| 09/18/2002 | EP1241254A1 Apoptosis inhibitory polypeptide, gene and polynucleotide encoding it and compositions containing the same |
| 09/18/2002 | EP1241176A1 Purine derivatives for the treatment of ischemia |
| 09/18/2002 | EP1241170A2 Pyrazolopyrimidine derivatives |
| 09/18/2002 | EP1241169A1 Isoindoloindolone derivatives, process for their preparation and pharmaceutical compositions containing them |
| 09/18/2002 | EP1241168A1 Human NK3 receptor-selective antagonist compounds, process for their obtention and pharmaceutical compositons containing them |
| 09/18/2002 | EP1240906A1 Preventives or remedies for arrhythmia |
| 09/18/2002 | EP1240823A1 N-calcium channel knockout animal |
| 09/18/2002 | EP1240335A2 Proteases |
| 09/18/2002 | EP1240313A2 Homologues of human heparanase and splice variants thereof |
| 09/18/2002 | EP1240202A2 Inhibitors of complement activation, their preparation and use |
| 09/18/2002 | EP1240201A1 Oxidized apolipoproteins and methods of use |
| 09/18/2002 | EP1240197A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1240194A2 Novel human protein kinases and protein kinase-like enzymes |
| 09/18/2002 | EP1240190A1 Uses of transport proteins for controlling cell cycle |
| 09/18/2002 | EP1240177A2 Benzophenone alpha-d-glycopyranosides, preparation and therapeutic use |
| 09/18/2002 | EP1240176A1 Benzophenone glycopyranosides, preparation and therapeutic use |
| 09/18/2002 | EP1240171A1 Cyclopenteneone derivatives |
| 09/18/2002 | EP1240168A1 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 09/18/2002 | EP1240164A1 Benzazole derivatives and their use as jnk modulators |
| 09/18/2002 | EP1240160A1 Substituted pyridazines having cytokine inhibitory activity |
| 09/18/2002 | EP1240158A1 1-(aminophenyl)-2-pyrrolidones as integrin inhibitors |
| 09/18/2002 | EP1240153A1 Aminothiazole inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240147A1 Potassium channel inhibitors |
| 09/18/2002 | EP1240146A1 2-arylquinoline derivatives, preparation and therapeutic use thereof |
| 09/18/2002 | EP1240145A2 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof |
| 09/18/2002 | EP1240144A2 Compound having effect of promoting neuron differentiation |
| 09/18/2002 | EP1239884A2 Methods for preparing pharmaceutical formulations |
| 09/18/2002 | EP1239877A2 MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN $g(a) V?$g(b) 3? RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 09/18/2002 | EP1239873A2 Method for localized administration of fibrinolytic metalloproteinases |
| 09/18/2002 | EP1239871A1 Use of glp-1 agonists for the inhibition of beta cell degeneration |
| 09/18/2002 | EP1239870A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1239869A2 Tweak receptor |
| 09/18/2002 | EP1239864A1 Treatment of heart rhythm disturbances with n6 -substituted-5'-(n-substituted) carboxamidoadenosines |
| 09/18/2002 | EP1239855A2 Method for the prevention and/or treatment of atherosclerosis |
| 09/18/2002 | EP1239854A1 Use of a hypoglycemic agent for treating impaired glucose metabolism |
| 09/18/2002 | EP1239848A2 Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| 09/18/2002 | EP1239846A2 Transdermal administration of phenylpropanolamine |
| 09/18/2002 | EP1239845A2 Hydroxide-releasing agents as skin permeation enhancers |
| 09/18/2002 | EP1239843A1 New (aminopropyl)methylphosphinic acids |
| 09/18/2002 | EP1117633B1 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 09/18/2002 | EP1039884B1 A method for the prevention and treatment of stunned myocardium |
| 09/18/2002 | EP1000034B1 Substituted 6-alkylphenanthridines |
| 09/18/2002 | EP0975573B1 Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
| 09/18/2002 | EP0934259B1 Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 09/18/2002 | EP0929516B1 Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect |
| 09/18/2002 | EP0904260B1 Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutyric acids |